Financing to drive new growth for Alter Pharma
Belgian pharmaceutical group Alter Pharma is a fast-growing player in the Life Sciences industry active in parallel import of medicines for the Belgium market. The company also develops generic medicines with a focus on niche products, and has successfully rolled-out over a dozen products in recent years.
Alter Pharma was established in 2010 by the van Rompay family, which has extensive knowledge of the regulated pharmaceutical market having previously founded and sold two pharmaceutical companies. To help the company’s entrepreneurial management team launch the next stage of its growth, private equity firm the Riverside Company, completed an investment in Alter Pharma in late 2017.
Riverside secured financing for the transaction through NIBC Leveraged Finance. NIBC acted as Mandated Lead Arranger alongside ING Belgium and Belfius Bank.
The Life Sciences & Health sector team supported with in-depth sector knowledge, which helped to assess and analyse the opportunity, the market and the value of the proposition. This proved to be vital in a highly specialised and regulated sector that Alter Pharma is active in. Furthermore, the transaction included facilities to cater for the growth prospect of the company.
The deal is NIBC’s first transaction with Riverside, which is an experienced player in the Healthcare industry and has global connections that can help specialist companies accelerate growth and increase market share.
We greatly appreciate NIBC’s support in making this investment possible. Alter Pharma is a highly innovative company that is led by an excellent management team. It will offer tremendous value potential in the years ahead. - Damien Gaudin, Vice President Riverside